Key result
Antihypertensive pharmacotherapy for primary hypertension in children over 6 years includes ACE inhibitors, ARBs, calcium channel blockers, thiazides, and beta-blockers, with dosing often extrapolated from adult data.
Why the study?
Due to the low prevalence of arterial hypertension in children, pharmacologic therapy is not routine pediatric practice, prompting a review of current pharmacotherapy recommendations and associated risks and benefits.
This review provides a basic orientation to current pharmacotherapy recommendations for primary hypertension in children over 6 years, highlighting potential benefits and risks of specific medications.
Supports individualized pharmacotherapy for primary hypertension in children >6 years; leaves open need for pediatric RCTs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Katrnošková et al. (2021) conducted a review in Primary hypertension. Antihypertensive pharmacotherapy was evaluated. Antihypertensive pharmacotherapy for primary hypertension in children over 6 years includes ACE inhibitors, ARBs, calcium channel blockers, thiazides, and beta-blockers, with dosing often extrapolated from adult data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: